Image: Epione Open Robotic Solution (Photo courtesy of Quantum Surgical)
Liver cancer is one of the leading causes of cancer death worldwide, with over three million people diagnosed with liver disease each year worldwide. Now, a unique robot-assisted technology dedicated to minimally invasive liver cancer treatment allows physicians to plan, target, deliver and confirm tumor removal.
Epione from Quantum Surgical (Montpellier, France) is the only all-in-one robot-assisted solution that provides multimodal pre-planning, robotic guidance and ablation confirmation. Epione is designed to help physicians plan, guide and evaluate percutaneous abdominal tumor ablation, a minimally invasive treatment in which a needle is inserted through the skin into the tumor to destroy it. Using the power of robotics and image fusion technology, Epione aims to provide clinicians with the ability to reach targeted tumors consistently.
The Epionen open robotic solution is compatible with all imaging systems. The medical robot is designed to allow doctors to choose from all ablative technologies (radiofrequency, microwave, cryoablation, irreversible electroporation) so that they can decide on the right therapy for each patient. It aims to make multiple probe procedures significantly easier, which will make the treatment of large tumors more predictable. Epione is the only interventional oncology robot that offers six degrees of freedom and unprecedented dexterity to access difficult trajectories when targeting abdominal tumors.
Following a successful multi-center clinical study completed in 2021, Epione received CE Mark approval and also obtained 510(k) clearance from the United States Food and Drug Administration (FDA), facilitating the treatment of liver disease at an early stage. The company plans to extend the indications of the Epione platform to other organs and is developing decision support functionalities based on artificial intelligence.
“This clearance gives interventional oncologists access to cutting-edge technology that has the potential to improve clinical outcomes and the lives of patients. We believe that the clinical adoption of innovative robotic solutions like Epione will be an important step in enabling more patients to benefit from minimally invasive therapies in the treatment of cancer,” said Bertin Nahum, president and co-founder of Quantum Surgical.
“Percutaneous tumor ablation is a proven therapy that is underutilized today, and Epione will help expand this minimally invasive treatment to more liver cancer patients,” said Nishita Kothary. , professor of radiology at Stanford University Medical Center.
“Epione ushers in an exciting new era by expanding technical capability and safety in the diagnosis and treatment of injury anywhere in the liver,” added Prof. Steven Colquhoun, Liver Transplant Surgeon, specializing in robotic surgery at Cedars. -Sinai Medical Center.